Application of 10-hydroxydecenoic acid in preparation of medicine for treating Parkinson's disease
By combining 10-hydroxydecenoic acid with meglumine to form a solubilized oral preparation, the problem of poor effectiveness of existing Parkinson's disease treatment drugs is solved, rapid and efficient treatment results are achieved, and safe Parkinson's disease treatment plan with fewer side effects.
Patent Information
- Application Number
- CN202311074095.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-08-24
- Publication Date
- 2024-11-19
AI Technical Summary
The existing Parkinson's disease treatment drugs are not effective, with obvious side effects, and lack efficient and safe anti-Parkinson's disease drugs.
10-hydroxydecenoic acid is combined with meglumine and an oral preparation is formed through solubilization technology, which promotes faster dissolution and absorption of 10-hydroxydecenoic acid in the body, thereby improving its anti-Parkinson disease therapeutic effect.
10-hydroxydecenoic acid significantly improved Parkinson's disease symptoms after 7 days of continuous administration, showing rapid and efficient anti-Parkinson's drug properties, and has fewer side effects and safety due to royal jelly.
Smart Images

Figure CN118976016A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and particularly relates to application of 10-hydroxydecenoic acid in preparing a drug for treating Parkinson's disease. Background Art
[0002] 10-Hydroxydecenoic acid, also known as royal jelly acid, comes from royal jelly, one of the bee products. Different from bee venom and propolis in its uses, characteristics and ingredients, royal jelly is a substance secreted by the glands in the head of the nurse bees in the honey bee colony. It is the food for the larvae that will become the queen bee and also the lifelong food of the queen bee. Royal jelly contains 62.5% to 70% water, and the rest are proteins, sugars, fatty acids, etc. The main active substances in royal jelly are proteins and fatty acids. For a long time, royal jelly has been used as a health care product widely used in the world. It is reported to have anti-hyperlipidemic, antioxidant, anti-proliferative, anti-microbial, neuroprotective, anti-inflammatory, immunomodulatory and anti-aging activities.
[0003] 10-Hydroxydecenoic acid (10-HDA, C 10 H 18 O 3 ) is a natural unsaturated fatty acid that is unique to royal jelly in nature and has always been regarded as an important indicator for measuring the quality of royal jelly and distinguishing its authenticity. 10-Hydroxydecenoic acid accounts for 50% of the total fatty acids in royal jelly and about 1.8% of the dry weight of royal jelly. 10-Hydroxydecenoic acid is a white crystal at room temperature, with stable properties, insoluble in water, soluble in methanol, ethanol, chloroform, slightly soluble in acetone, and has a melting point of 64°C. Normally, 10-Hydroxydecenoic acid can be isolated from royal jelly or synthesized artificially.
[0004] Parkinson's disease (PD) is a common degenerative disease of the central nervous system. The disease was first systematically described by British doctor James Parkinson. PD mainly affects the motor nervous system, and clinical symptoms mainly include motor symptoms (resting tremor, rigidity, abnormal gait, etc.) and non-motor symptoms (sleep disorders, cognitive impairment, anxiety, depression, etc.). The main pathological characteristics of PD include: a significant decrease in the content of dopamine (DA) in the striatum, degeneration and death of dopaminergic neurons (SN) in the substantia nigra of the midbrain, and the appearance of eosinophilic inclusions composed of α-synuclein (a-Syn) in the substantia nigra, namely Lewy bodies. In addition, PD can also affect other brain regions, including cholinergic neurons (CN) in the nucleus basalis of Meynert, noradrenergic neurons (NN) in the locus coeruleus, dorsal motor nucleus of the vagus nerve, raphe nuclei in the brainstem, cerebral cortex and hypothalamus. The above pathological changes jointly affect the motor symptoms and non-motor symptoms of PD. Among them, the significant decrease in striatal DA content is mainly closely related to PD motor symptoms, while changes in the midbrain-limbic system and midbrain-cortical system are closely related to PD non-motor symptoms such as cognitive impairment and mood disorders. However, to date, surgical treatment and existing drugs (such as levodopa, amantadine, selegiline, etc.) have low efficacy and unsatisfactory effects. At present, the mainstream surgical treatment for PD is deep brain stimulation (DBS) therapy, but there are problems such as psychological barriers of patients, high treatment costs and strict technical conditions, which is not suitable for most PD patients. The main anti-PD drugs in clinical practice include: anticholinergic drugs such as trihexyphenidyl (which can easily cause side effects such as slow reaction, mental disorders and cognitive decline); amantadine (long-term use may cause livedo reticularis on the skin of the lower limbs and edema of the lower legs); DA supplements such as levodopa (poor efficacy on tremor, induces dyskinesia, and high doses are prone to gastrointestinal reactions such as nausea and vomiting); DA receptor agonists such as pramipexole (which can easily induce postural hypotension, gastrointestinal reactions and mental symptoms); type B monoamine oxidase inhibitors such as selegiline (causing insomnia, gastrointestinal reactions, etc.); catechol-O-methyltransferase inhibitors such as tolcapone (side effects include insomnia, movement disorders, etc.). In summary, most drug treatments can only relieve the condition, the effect is not satisfactory, and the side effects are obvious. There is a lack of targeted, more efficient, better-effective, and fewer side effects therapeutic drugs. New and efficient anti-PD drugs are urgently needed in clinical practice. Summary of the invention
[0005] One of the purposes of the present invention is to provide application of 10-hydroxydecenoic acid in preparing a drug for treating Parkinson's disease.
[0006] Furthermore, the therapeutic drug is an oral preparation, an injection, a suppository, or a transdermal preparation.
[0007] The second purpose of the present invention is to provide the use of 10-hydroxydecenoic acid oral preparation in the preparation of Parkinson's disease therapeutic drugs.
[0008] Furthermore, the oral preparation is selected from oral solution, granules, capsules, ordinary tablets, dropping pills, micropills, oral film tablets, dispersible tablets, effervescent tablets, and sustained-release tablets.
[0009] Furthermore, the oral preparation contains meglumine.
[0010] The present invention has found that meglumine is used to solubilize 10-hydroxydecenoic acid to form a completely dissolved true solution, which achieves an unexpected effect in treating Parkinson's disease. At the same time, the method of adding meglumine to the auxiliary material to prepare a 10-hydroxydecenoic acid solid preparation, such as a tablet, promotes the faster dissolution of 10-hydroxydecenoic acid from the tablet, which is beneficial for 10-hydroxydecenoic acid to play a better anti-Parkinson's disease therapeutic effect.
[0011] Beneficial effects: The present invention proves through experiments that 10-hydroxydecenoic acid can significantly improve PD symptoms after continuous administration for 7 days. This shows that 10-hydroxydecenoic acid is a fast and efficient anti-PD drug. Since 10-hydroxydecenoic acid is derived from royal jelly, a commonly used and popular high-end health product, it is convenient and safe to take orally, and has few side effects. Therefore, the present invention provides strong support for the research and development of anti-PD drugs and is of great significance. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 The results of the anti-PD effect of 10-hydroxydecenoic acid solution administered by gavage on MPTP model mice in Test Example 1. A is the experimental design of modeling, drug administration and PD index testing; BC is the result of open field test 7 days after drug administration; D is the result of rotarod test 8 days after drug administration; E is the result of Y maze test 10 days after drug administration. One-way ANOVA analysis was used, *p<0.05, **p<0.01, ***p<0.001.
[0013] Figure 2The results of the exposure levels in rats after oral administration of 10-hydroxydecenoic acid solution in Test Example 2. A is the exposure level of 10-hydroxydecenoic acid in plasma; B is the exposure level of 10-hydroxydecenoic acid in hippocampus; C is the exposure level of 10-hydroxydecenoic acid in striatum. One-way ANOVA analysis was used, *p<0.05, **p<0.01, ***p<0.001.
[0014] Figure 3 These are the dissolution results of 10-hydroxydecenoic acid tablets in Test Example 3. A is the dissolution in artificial gastric juice; B is the dissolution in artificial intestinal juice.
[0015] Figure 4 The results of the effect of 10-hydroxydecenoic acid on dopamine in major brain tissues in Test Example 4. A is the dopamine level in the hippocampus; B is the dopamine level in the striatum; C is the dopamine level in the cortex. One-way ANOVA analysis was used, *p<0.05. DETAILED DESCRIPTION
[0016] The following embodiments can enable those skilled in the art to more fully understand the present invention, but the present invention is not limited to the scope of the embodiments.
[0017] Example 110-Study on the solubilization formula of hydroxydecenoic acid liquid preparation
[0018] 10-Hydroxydecenoic acid is poorly soluble in water. The pharmaceutical method was used to add solubilizing means such as cosolvents to investigate the solubility state and stability. The prescription was studied according to the dosage in Table 1, and the solution was prepared and packaged in EP tubes, each tube was about 1.5 ml, and placed at room temperature and refrigerated at 4°C. Observe the state of the solution. It was found that prescriptions 2 and 3 were turbid or had a small amount of undissolved precipitation, and no obvious changes were observed after being placed at room temperature or refrigerated at 4°C. After preparation, prescriptions 1, 4, and 5 were placed at room temperature for 3 days and refrigerated at 4°C for three days, and they were stable, clear and transparent (Table 1).
[0019] Table 11 Study on the solubilization formula of 0-hydroxydecenoic acid liquid preparation
[0020]
[0021] Example 2 Preparation of 10-Hydroxydecenoic Acid Oral Solution
[0022] Based on the prescription research results of prescription 5 in Example 1, 10-hydroxydecenoic acid oral solution was prepared with meglumine as a cosolvent, with the goal of dissolving 10-hydroxydecenoic acid to form a stable true solution, and purified water as a dispersing solvent, with specifications ①-② being 90 and 180 mg / 5 mL, respectively. The prescription is as follows:
[0023]
[0024]
[0025] Preparation process: Weigh 6.0 grams of meglumine, add it to 50 mL of pure water to dissolve, then weigh 1.8 g / 3.6 g of 10-hydroxydecenoic acid respectively, dissolve them in the above solution, add pure water to 100 mL, shake and mix, filter with 0.8 micron microporous membrane, and package. The unit preparation is 5 mL, containing 90 mg or 180 mg of 10-hydroxydecenoic acid respectively.
[0026] Example 3 Preparation of 10-Hydroxydecenoic Acid Oral Suspension
[0027] Based on the results of the prescription study of prescription 5 in Example 1, the 10-hydroxydecenoic acid suspension was prepared without aiming at dissolving 10-hydroxydecenoic acid, and the specifications ①-② were 90 and 180 mg / 5 mL, respectively. The prescription is as follows:
[0028] 10-Hydroxydecenoic acid 1.8g / 3.6g
[0029] Sodium carboxymethyl cellulose 0.5g
[0030] Add distilled water to 100 mL
[0031] Preparation process: Weigh 1.8g / 3.6g of 10-hydroxydecenoic acid respectively, pass through a 60-mesh sieve; take 0.5g of sodium carboxymethyl cellulose (CMC-Na) and pass through an 80-mesh sieve. Disperse and dissolve sodium carboxymethyl cellulose in 100mL of distilled water, disperse and suspend 10-hydroxydecenoic acid in 0.5% sodium carboxymethyl cellulose aqueous solution, and oscillate to suspend evenly. Each preparation of 5mL contains 90mg or 180mg of 10-hydroxydecenoic acid respectively.
[0032] Example 4 Preparation of 10-Hydroxydecenoic Acid Tablets
[0033] Preparation of 10-hydroxydecenoic acid tablets, specifications ①-② are 90 and 180 mg / tablet respectively. The prescription is as follows:
[0034]
[0035] Preparation process: according to the above prescription, weigh 10-hydroxydecenoic acid, compressible starch, sodium carboxymethyl starch, pass through 80 mesh sieve respectively, and mix evenly; take 5g of povidone, dissolve in about 9 ml of 30% ethanol solution, make soft material by conventional method, pass through 20 mesh sieve to granulate, circulate and dry at 60℃ for 2 hours, add micro powder silica gel (pass through 120 mesh sieve), mix evenly, and press into tablets. Prepare 100 tablets, each tablet is about 0.44 or 0.53g, containing 90mg or 180mg of 10-hydroxydecenoic acid.
[0036] Example 5 Preparation of 10-hydroxydecenoic acid tablets containing meglumine
[0037] Preparation of 10-hydroxydecenoic acid tablets containing meglumine, specifications ①-② are 90 and 180 mg / tablet respectively. The prescription is as follows:
[0038]
[0039] Preparation process: according to the above prescription, weigh 10-hydroxydecenoic acid, compressible starch, sodium carboxymethyl starch, and meglumine, pass through an 80-mesh sieve respectively, and mix evenly; prepare a soft material with 30% ethanol solution, pass through a 20-mesh sieve to granulate, circulate and dry at 60°C for 2 hours, add micro powder silica gel (pass through a 120-mesh sieve), mix evenly, and press into tablets. Prepare 100 tablets, each tablet is about 0.54 or 0.78g, containing 90mg or 180mg of 10-hydroxydecenoic acid.
[0040] Example 6 Preparation of 10-Hydroxydecenoic Acid Capsules
[0041] Preparation of 10-hydroxydecenoic acid capsules, specifications ①-② are 90 and 180 mg / capsule respectively. The prescription is as follows:
[0042]
[0043] Preparation process: According to the above prescription, 10-hydroxydecenoic acid, microcrystalline cellulose and lactose are weighed respectively, passed through a 60-mesh sieve respectively, and mixed evenly; an appropriate amount of 0.5% sodium carboxymethyl cellulose is added to make a soft material, granulated with a 15-mesh sieve, dried at 60°C for 2 hours, granulated after drying, and filled into No. 1 and No. 0 ordinary capsules respectively. Each preparation contains 0.19 or 0.28 g of granules, which contain 90 and 180 mg of 10-hydroxydecenoic acid respectively.
[0044] Example 7 Preparation of 10-Hydroxydecenoic Acid Effervescent Tablets
[0045] 10-Hydroxydecenoic acid effervescent tablets were prepared, with specifications ①-② being 90 and 180 mg / tablet, respectively. The prescription is as follows:
[0046]
[0047]
[0048] Preparation process: Weigh 10-hydroxydecenoic acid according to the above prescription, dissolve it in 30 ml of medicinal ethanol, and use it as component A for standby; take compressible starch, sodium carboxymethyl starch, sodium bicarbonate, meglumine, and citric acid and dry them thoroughly, weigh them according to the above prescription, pass them through an 80-mesh sieve, mix them evenly, add component A-10-hydroxydecenoic acid ethanol solution and mix them evenly, and use it as component B for standby; take 3g of povidone, dissolve it in about 12 ml of polyethylene glycol 400 solution, add it to component B, make soft material by conventional method, pass it through a 15-mesh sieve for granulation, dry it at 60℃ for 3 hours, add micro powder silica gel (pass through a 120-mesh sieve), mix it evenly, and press it into tablets. Prepare 100 tablets, each tablet is about 1.29 or 1.65g, containing 180mg or 360mg of 10-hydroxydecenoic acid.
[0049] Test Example 1 Anti-PD Effect of 10-Hydroxydecenoic Acid on MPTP Model Mice
[0050] Animal species selection: C57BL / 6J mice (male, 7-8 weeks old, purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., weighing 21±3g) were used and adaptively raised for one week under a standard breeding environment (free food and water, alternating day and night, 12 hours each).
[0051] Establishment of animal model: After seven days of adaptive culture of C57BL / 6J mice, the PD mouse model was established by intraperitoneal injection of the modeling agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) at a dose of 20 mg / kg for 14 consecutive days. MPTP can cross the blood-brain barrier and be converted into the metabolite 1-methyl-4-phenylpyridinium ion (MPP) in astrocytes. + ), which in turn leads to ATP production disorder, intracellular Ca 2+ The level of reactive oxygen and reactive nitrogen generated caused apoptosis of dopaminergic neurons. On the fourth day of modeling, the mice were randomly divided into model group, true solution group, and suspension group for experiment ( Figure 1 (A).
[0052] Administration method: PD model mice were gavaged with 10-hydroxydecenoic acid at a dose of 180 mg / kg (true solution group and suspension group) according to Example 2 and Example 3, respectively, and the control group and model group were given an equal volume of 0.5% CMC-Na solution.
[0053] Effect on the motor behavior of mice: Social behavior was evaluated after 7 consecutive days of administration. Before the experiment, the mice were placed in a behavioral test room to adapt to the light and temperature for more than 30 minutes. C57BL / 6J mice were placed in an open field of 50×50×50cm, and a single experimental animal was placed in the center of the open field. They were allowed to move freely for 5 minutes and the activities of the C57BL / 6J mice were recorded within 300 seconds. After the experiment, the mice were removed. After the experiment, alcohol was sprayed to eliminate the smell and the experiment on the next animal was carried out. The activity distance and time of the experimental animals in the central area and the peripheral area were analyzed to evaluate the spontaneous activity of the experimental animals. The results showed that compared with the blank control group, the ratio of the central area movement distance of the PD model group mice to the total distance decreased significantly, while the central area ratio of the true solution group and the suspension group mice increased significantly, and the efficacy of the true solution group was better than that of the suspension group ( Figure 1 In addition, the time the mice stayed in the central area also showed ( Figure 1 In the middle C), the time spent in the center area by the mice in the PD model group was significantly shorter than that in the blank control group, while the time spent in the center area by the mice in the true solution group was significantly longer, and the center stay time by the mice in the suspension group was slightly longer, but no significant difference was observed (p = 0.1154). These results indicate that oral administration of 10-hydroxydecenoic acid can improve the autonomous movement ability and anxiety-like behavior of PD mice, and that meglumine as a cosolvent is beneficial to the efficacy of the drug.
[0054] The rotarod fatigue instrument was used to evaluate the motor ability of experimental mice. The experimental animals were adapted to the rotarod instrument at a speed of 4 rpm / min for 10 minutes, and then rested for 30 minutes. The speed was set to 35 rpm / min, the time was 5 minutes, and the acceleration time was 30 seconds. The time (latency) that each experimental animal remained on the rotarod was recorded. The experimental results showed that ( Figure 1 In D), the latency of mice in the PD model group on the rotarod was significantly reduced compared with the empty control group, while the latency of mice in the drug-treated group was significantly increased, and the effect of the true solution group was better than that of the suspension group. The rotarod experiment showed that 10-hydroxydecenoic acid can improve the motor ability of PD mice, and meglumine as a cosolvent is conducive to further exerting the drug effect.
[0055] Cognitive impairment is one of the common non-motor symptoms of PD, including Parkinson's disease mild cognitive impairment (PD-MCI) and Parkinson's disease dementia (PDD). It is also an important reason that affects the quality of life of patients and accelerates the progression of the disease. The Y-maze experiment was used to evaluate the spatial memory and cognitive ability of experimental mice. Alternation behavior is the nature of experimental animals to explore new environments. During the search process, experimental animals need to remember the direction they explored last time to avoid repeated entry. Therefore, the Y-maze experiment can effectively measure the spatial memory ability of the experiment. The experimental mouse was placed at the end of any arm and allowed to explore freely in the Y-maze for 5 minutes. The total number of times the mouse entered each arm was recorded. All four feet of the mouse entered the arm once, and alternation once refers to entering three different arms of the maze in sequence (123, 132, 312, etc.), the maximum number of turns refers to the total number of arms - 2, and the alternation percentage = total number of turns / maximum number of turns × 100%. The experimental results showed that the MPTP-induced PD model showed a decrease in the alternation percentage, indicating that the MPTP-induced PD model is also accompanied by cognitive impairment and memory loss. The alternation percentage of mice in the 10-hydroxydecenoic acid group was significantly increased, which alleviated the MPTP-induced spatial memory cognitive impairment and enhanced their desire to explore, and the level was comparable to that of the blank control group. This shows that 10-hydroxydecenoic acid can improve MPTP-induced cognitive impairment and memory damage.
[0056] In summary, the administration of 10-hydroxydecenoic acid can significantly improve the autonomous movement ability and memory cognition ability of MPTP-induced PD model mice, and the behavioral effect of mice in the true solution group is better than that in the suspension group, indicating that meglumine in the oral solution is conducive to the better anti-PD pharmacological effect of 10-hydroxydecenoic acid.
[0057] Test Example 2 Study on the Effect of Meglumine on the Drug Concentration of 10-Hydroxydecenoic Acid in Rat Plasma and Tissue
[0058] Animals and administration method: 16 SD rats aged 6-7 weeks (weight 200 ± 20g), half male and half female, were randomly divided into 2 groups according to body weight, 8 rats in each group (half male and half female). Free food and water were allowed to adapt to the environment for one week before administration. Fasting for 12 hours before the experiment, but water was not allowed. The suspension without meglumine and the solution containing meglumine in Examples 2 and 3 were respectively used for oral administration (180 mg / kg). 200 μL of blood samples were collected at 2, 5, 10, 20, 40, 60, 120, 240, and 360 minutes after administration, added to the sodium heparin EP tube, centrifuged at 5000rpm for 5 minutes, and the plasma supernatant was separated and stored in a -80°C refrigerator for standby use. Animals were grouped and administered in the same manner as above, and rats were anesthetized and killed 10 and 40 minutes after administration, respectively, and the hippocampus, cortex, and striatum were collected. The tissues were washed with ice physiological saline solution, and after being dried with absorbent paper, they were stored in a -80°C refrigerator for standby use.
[0059] Quantitative determination method of 10-hydroxydecenoic acid: LC-MS / MS analysis was performed using a Shimadzu high performance liquid chromatograph (including a SIL-20ACXR constant temperature automatic sampler, a CTO-20A column oven, and a DGU-20A3 online vacuum degasser), connected in series with an American AB mass spectrometer system (API 5500), an electrospray ion source (ESI), and an Analyst 1.6.1 workstation.
[0060] Plasma and tissue samples were treated with organic solvent protein precipitation and centrifuged twice (4°C, 18000rpm centrifugation for 5min), and 5μL of the supernatant was injected. The chromatographic column was Agilent ZORBAX Eclipse Plus C18 (2.1×50mm, 3.5-μm), the column temperature was 40°C, and the mobile phase was methanol-0.02% ammonium formate aqueous solution. The gradient elution method was adopted with a flow rate of 0.3ml / min. In the electrospray ionization (ESI) mode, the ion spray voltage was -4500V; auxiliary gas 1 and 2 were both nitrogen: 50Arb, 55Arb; auxiliary gas temperature was 500°C; curtain gas was 30Arb; collision gas: 10Arb; inlet voltage EP: -10V; outlet voltage CXP: -5V. Multiple reaction monitoring (MRM) mode was used to detect negative ions. The ion pair of 10-hydroxydecenoic acid detection was 185.00→139.00. CE: -22eV; DP: -70V were set. The internal standard was chlorzoxazone. In the ESI negative ion mode, the ion pair was 168.00→132.00. In addition, a series of standard solutions were prepared and the sample determination method was used to draw the working curve and calculate the concentration level of 10-hydroxydecenoic acid in plasma and tissue samples.
[0061] Results: After the administration of solution and suspension, the drug concentration in plasma increased rapidly in a short period of time (10 minutes after administration), and then decreased significantly ( Figure 2 A), indicating that 10-hydroxydecenoic acid can be rapidly absorbed in the gastrointestinal tract. In addition, the exposure level of 10-hydroxydecenoic acid in plasma after administration in the form of true solution was significantly higher than that after administration in the form of suspension, indicating that meglumine solubilization is beneficial to increase the exposure level of 10-hydroxydecenoic acid in the circulatory system.
[0062] The drug concentration levels in the central hippocampus and striatum increased within a short period of time after administration (10 minutes after administration), and then decreased significantly, indicating that 10-hydroxydecenoic acid easily enters the central tissue. In addition, after 10-hydroxydecenoic acid was administered in the form of a true solution, the overall exposure level in the hippocampus and striatum was higher than that of the suspension ( Figure 2 B, 2C), suggesting that meglumine solubilization is beneficial to increase the exposure level of 10-hydroxydecenoic acid in the central nervous system, especially in tissues such as the hippocampus and striatum.
[0063] Conclusion: After oral administration of 10-hydroxydecenoic acid, the exposure level in the blood and brain tissue (hippocampus, cortex, and striatum) of SD rats was high. Meglumine can significantly increase the exposure level of 10-hydroxydecenoic acid in plasma, hippocampus, and striatum, suggesting that it is beneficial to the anti-PD effect.
[0064] Test Example 3 Dissolution of 10-Hydroxydecenoic Acid Tablets in Simulated Artificial Gastric / Intestinal Fluids in Vitro
[0065] 1. Solubility in artificial gastric juice:
[0066] The simulated artificial gastric juice was prepared by the paddle method according to the pharmacopoeia method, and the pH was adjusted to about 1.5. 900 ml of artificial gastric juice was added to each dissolution cup. After the temperature reached and equilibrated at 37°C, one tablet of 10-hydroxydecenoic acid tablets without meglumine in Example 4 and one tablet of 10-hydroxydecenoic acid tablets containing meglumine in Example 5 were placed in six dissolution cups, and the rotation speed was adjusted to 80 rpm. 1 ml of filtrate was taken at 5, 15, 30, 45, and 60 minutes, and the LC-MS / MS method for determining the acidity of 10-hydroxydecenoic acid in the above test example 2 was used to calculate the dissolved amount of 10-hydroxydecenoic acid, and the dissolved percentage was calculated by comparing with the labeled amount. The dissolution curve was drawn to compare the dissolution difference of the two tablets.
[0067] Results: Both tablets disintegrated quickly in artificial gastric juice, and the solution became turbid. The test results showed that 10-hydroxydecenoic acid dissolved slowly in artificial gastric juice, and the solubility increased with time. At 60 minutes, the average solubility of 10-hydroxydecenoic acid tablets without meglumine was 32.3%, and the average solubility of 10-hydroxydecenoic acid tablets with meglumine was 44.8%. Figure 3 A.
[0068] Conclusion: The dissolution of 10-hydroxydecenoic acid in artificial gastric juice is relatively slow, and meglumine has a certain promoting effect on the dissolution of 10-hydroxydecenoic acid in artificial gastric juice.
[0069] 2. Dissolution in artificial intestinal fluid:
[0070] The simulated artificial intestinal fluid was prepared by the paddle method according to the pharmacopoeia method, and the pH was adjusted to about 6.8. 900 ml of artificial intestinal fluid was added to each dissolution cup. After the temperature reached and equilibrated at 37°C, one tablet of 10-hydroxydecenoic acid tablet without meglumine in Example 4 and one tablet of 10-hydroxydecenoic acid tablet with meglumine in Example 5 were placed in six dissolution cups, and the rotation speed was adjusted to 80 rpm. 1 ml of filtrate was taken at 5, 15, 30, 45, and 60 minutes respectively. After dilution, the acidity of 10-hydroxydecenoic acid was determined by LC / MS method, the amount of 10-hydroxydecenoic acid dissolved was calculated, and the percentage of dissolution was calculated by comparing with the labeled amount. The dissolution curve was drawn to compare the dissolution difference of the two tablets.
[0071] Results: Both tablets disintegrated quickly in artificial intestinal fluid, and the solution became turbid. The test results showed that 10-hydroxydecenoic acid dissolved quickly in artificial intestinal fluid, and the solubility increased with time. At 60 minutes, the average solubility of 10-hydroxydecenoic acid tablets without meglumine was 69.7%, and the average solubility of 10-hydroxydecenoic acid tablets with meglumine was 98.2%. Figure 3 B.
[0072] Conclusion: 10-hydroxydecenoic acid dissolves quickly in artificial intestinal fluid, and 10-hydroxydecenoic acid in the tablet containing meglumine dissolves fully at 60 minutes, indicating that meglumine can promote the dissolution of 10-hydroxydecenoic acid in the intestinal physiological environment. Compared with artificial gastric juice, 10-hydroxydecenoic acid dissolves more easily in the simulated intestinal physiological environment, suggesting that it is beneficial to its absorption in vivo.
[0073] Test Example 4 Effect of 10-hydroxydecenoic acid on dopamine levels in the brain of AD model rats
[0074] Animal species selection: SD rats (male, 6-7 weeks old, purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., weighing 200±20g) were used and adaptively raised for one week under a standard breeding environment (free diet and drinking water, alternating day and night, 12 hours each).
[0075] Establishment of animal model: Ibotenic acid (IBO) is a neurotoxin. Intracranial injection of IBO damages the nucleus basalis of Meynert and its cholinergic nervous system, causing neuronal damage and cognitive impairment in the animal model. After seven days of adaptive culture of SD rats, IBO was injected into the striatum using a brain stereotaxic instrument. After intraperitoneal anesthesia, the experimental animals were fixed on the brain stereotaxic instrument, the head skin was disinfected and cut open, the subcutaneous tissue was separated, and the skull was exposed. Referring to the Paxinos rat brain stereotaxic atlas (coordinates: 1.0mm behind the anterior fontanelle, 2.7mm beside the midline, 7.0mm deep), the skull was drilled at the location with a skull drill, and 2μL of IBO solution (dissolved in sterile saline, concentration 1.25μg / μL) was slowly injected on each side, and the control group was injected with the same volume of sterile saline.
[0076] Administration and sample collection: PD model mice were gavaged with 10-hydroxydecenoic acid (true solution group and suspension group) at a dose of 180 mg / kg according to Example 2 and Example 3, and the control group and model group were given an equal volume of 0.5% CMC-Na solution. Brain tissue samples such as striatum, hippocampus, and cortex were collected one week after administration, and dopamine levels were determined using LC-MS / MS technology to compare the difference in DA after administration of true solution and suspension.
[0077] Results: Compared with the control group, the DA levels in the striatum and hippocampus of IBO model rats were decreased, while 10-hydroxydecenoic acid could increase the DA levels in the striatum and hippocampus, and the true solution of 10-hydroxydecenoic acid containing meglumine was more effective ( Figure 4 AB).
[0078] Conclusion: 10-hydroxydecenoic acid can increase the DA levels in the hippocampus and striatum of IBO model rats. The 10-hydroxydecenoic acid solution containing meglumine can significantly increase the DA levels in the hippocampus and striatum, suggesting that 10-hydroxydecenoic acid is conducive to exerting a better anti-PD effect.
Claims
1. Application of 10-hydroxydecenoic acid in the preparation of drugs for the treatment of Parkinson's disease.
2. The use according to claim 1, characterized in that: The therapeutic medicine is an oral preparation, an injection, a suppository, or a transdermal preparation.
3. Application of 10-hydroxydecenoic acid oral preparation in the preparation of drugs for the treatment of Parkinson's disease.
4. The use according to claim 3, characterized in that: The oral preparation is selected from oral solution, granules, capsules, ordinary tablets, dropping pills, micropills, oral film tablets, dispersible tablets, effervescent tablets, and sustained-release tablets.
5. The use according to claim 4, characterized in that: The oral formulation contains meglumine.
